Standard BioTools Inc.

LABNASDAQHealthcare● Active

$0.83

$-0.32(-27.90%)

Market Cap$323654206

P/E Ratio—

52W High$1.72

52W Low$0.8087

Avg Volume2.5M

Open$1.14

Beta1.38

Free Cash Flow Financials Revenue

Standard BioTools Inc. (LAB) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LAB · free cash flow · updated Jun 8, 2026

Core FCF metrics

LAB · FCF · TTM · margin & CAGR

Free cash flow was −$82.7M for FY2025 (fiscal year ending 2025-12-31), up 45.6% year-over-year The FCF margin was -96.9%.

FY2025 Free Cash Flow−$82.7M▲ +45.6% YoY

Trailing 12M (TTM)−$94.5Mtrailing 4 quarters sum

FCF Margin-96.9%−$82.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LAB · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$74.3M(8M)−$82.7M▲ +45.6%-96.9%

FY2024−$143.5M(8M)−$151.8M▼ 229.2%-87.0%

FY2023−$43.3M(3M)−$46.1M▲ +50.5%-43.4%

FY2022−$89.4M(4M)−$93.2M▼ 62.6%-95.2%

FY2021−$44.1M(13M)−$57.3M▼ 103.8%-43.9%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LAB · P/FCF · FCF yield · FCF per share

Standard BioTools Inc. (LAB) reported negative free cash flow of −$0.08B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

LAB · cash flow statement · operating / investing / financing

For FY2025, Standard BioTools Inc. generated −$74.3M in operating cash flow and spent 8M in capital expenditures, yielding −$82.7M in free cash flow.

Operating Activities

−$74.3M

Cash from core business operations

2025-12-31

Investing Activities

+$24.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$0.6M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$74.3M) − |CapEx| (8M) = FCF (−$82.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LAB vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Standard BioTools Inc.YOU

LAB

−$82.7M+45.6%-96.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Standard BioTools Inc. (LAB) reported free cash flow of −$82.7M for FY2025 (fiscal year ending 2025-12-31), up 45.6% year-over-year. The FCF margin was -96.9%.

Standard BioTools Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LAB free cash flow · 8 questions

Standard BioTools Inc. free cash flow was −$82.7M for FY2025, up 45.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$94.5M.

LAB free cash flowLAB FCFLAB FCF 2025LAB free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Standard BioTools Inc. · Standard BioTools Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026